Physician profile
William T Boulware
NPI 1023190493
$6,540.84
in general payments reported to CMS, 2019-2025
58 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $556 · 2021: $879 · 2022: $786 · 2023: $894 · 2024: $1,143 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,317.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $841.37 | 2021-2025 | Ubrelvy, Linzess, Qulipta |
| Novo Nordisk INC | $472.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $462.52 | 2019-2025 | |
| Lilly USA, LLC | $458.92 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $407.37 | 2020-2025 | Repatha, Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $256.80 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.10 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $209.59 | 2023-2025 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $207.80 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $203.01 | 2019-2024 | Verquvo, Belsomra |
| Astrazeneca Pharmaceuticals LP | $178.15 | 2020-2025 | Airsupra, Fasenra, Farxiga |
| Abbott Laboratories | $165.88 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $145.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.07 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $127.61 | 2019-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Boulware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.